Target Name: DPEP1
NCBI ID: G1800
Review Report on DPEP1 Target / Biomarker Content of Review Report on DPEP1 Target / Biomarker
DPEP1
Other Name(s): MDP | beta-lactamase | microsomal dipeptidase | Beta-lactamase | RDP | MBD1 | renal dipeptidase | Dehydropeptidase-I | dipeptidase 1 | Dipeptidase 1, transcript variant 1 | Microsomal dipeptidase | DPEP1_HUMAN | DPEP1 variant 1 | Dipeptidase 1 (isoform a) | Dipeptidase 1 | testicular tissue protein Li 57 | dehydropeptidase-I | Renal dipeptidase | dipeptidase 1 (renal) | hRDP

DPEP1: A Potential Drug Target and Biomarker

Dopamine-producing enzyme 1 (DPEP1) is a gene that encodes a protein involved in the production of dopamine in the brain. Mutations in the DPEP1 gene have been linked to various neurological disorders, including Parkinson's disease, addiction, and schizophrenia. Therefore, targeting DPEP1 has the potential to treat a range of debilitating neurological disorders.

The DPEP1 gene has been the focus of intense research in recent years due to its involvement in the production of dopamine, which is a neurotransmitter that plays a crucial role in various brain functions, including motivation, pleasure, and movement control. Dopamine is also involved in the development of neuroplasticity, which is the ability of the brain to change and adapt throughout a person's life.

Studies have shown that individuals with genetic mutations that affect the DPEP1 gene are at increased risk of developing neurological disorders. For example, individuals with the DOP9 gene, which is associated with Parkinson's disease, are estimated to have a risk of developing the disease of up to 70%. Similarly, individuals with the DPEP1 gene have a higher risk of developing addiction and schizophrenia.

The potential drug target for DPEP1 is derived from its involvement in the production of dopamine. By inhibiting the activity of DPEP1, researchers have found that they can reduce the production of dopamine in the brain, which can lead to the therapeutic treatment of various neurological disorders. For example, studies have shown that inhibiting DPEP1 can reduce the risk of developing Parkinson's disease and improve symptoms in individuals with the disease.

In addition to its potential therapeutic applications, DPEP1 is also a promising biomarker for various neurological disorders. The DPEP1 gene has been used to generate antibodies that can detect DPEP1 protein in brain tissue, which could be used as a diagnostic tool for neurological disorders. Additionally, DPEP1 has been shown to be involved in the development of neuroplasticity, which could be used as a biomarker for the assessment of neuroplasticity in individuals with neurological disorders.

In conclusion, DPEP1 is a gene that has the potential to be a drug target for the treatment of a range of neurological disorders. Further research is needed to fully understand the role of DPEP1 in neurological development and disease, as well as the development of biomarkers for its dysfunction. However, the potential of DPEP1 as a drug target and biomarker is a promising area of research that could lead to new treatments for a variety of debilitating neurological disorders.

Protein Name: Dipeptidase 1

Functions: Hydrolyzes a wide range of dipeptides including the conversion of leukotriene D4 to leukotriene E4 (PubMed:2303490, PubMed:6334084, PubMed:31442408, PubMed:32325220). Hydrolyzes cystinyl-bis-glycine (cys-bis-gly) formed during glutathione degradation (PubMed:32325220). Possesses also beta lactamase activity and can hydrolyze the beta-lactam antibiotic imipenem (PubMed:6334084, PubMed:32325220)

The "DPEP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPEP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DPEP2 | DPEP3 | DPF1 | DPF2 | DPF3 | DPH1 | DPH2 | DPH3 | DPH3P1 | DPH5 | DPH5-DT | DPH6 | DPH6-DT | DPH7 | DPM1 | DPM2 | DPM3 | DPP10 | DPP10-AS1 | DPP3 | DPP3-DT | DPP4 | DPP6 | DPP7 | DPP8 | DPP9 | DPP9-AS1 | DPPA2 | DPPA2P3 | DPPA3 | DPPA3P1 | DPPA3P2 | DPPA4 | DPPA4P3 | DPPA5 | DPPA5P4 | DPRX | DPRXP2 | DPRXP4 | DPT | DPY19L1 | DPY19L1P1 | DPY19L2 | DPY19L2P1 | DPY19L2P2 | DPY19L2P3 | DPY19L2P4 | DPY19L3 | DPY19L3-DT | DPY19L4 | DPY30 | DPYD | DPYD-AS1 | DPYS | DPYSL2 | DPYSL3 | DPYSL4 | DPYSL5 | DQX1 | DR1 | DRAIC | DRAM1 | DRAM2 | DRAP1 | DRAXIN | DRB sensitivity-inducing factor complex | DRC1 | DRC3 | DRC7 | DRD1 | DRD2 | DRD3 | DRD4 | DRD5 | DRD5P1 | DRD5P2 | DRG1 | DRG2 | DRGX | DRICH1 | DROSHA | DRP2 | DSC1 | DSC2 | DSC3 | DSCAM | DSCAM-AS1 | DSCAML1 | DSCC1 | DSCR10 | DSCR4 | DSCR8 | DSCR9 | DSE | DSEL | DSEL-AS1 | DSG1 | DSG1-AS1 | DSG2 | DSG3